

TRACER (S1415CD) NEWSLETTER



November/December 2019

NOTICE FOR SITES

Please be advised of an upcoming change to accrual for S1415CD.

Effective December 2, 2019:

- Cohort sites (Group 1) will close all accrual.
- Randomized sites (Groups 2, 3, and 4) will close accrual only to patients on low- and high-risk regimens.
- Randomized sites (Groups 2, 3, and 4) can continue to accrue patients on intermediate-risk regimens **through March 31, 2020.**

TrACER: A Pragmatic Trial Assessing CSF Prescribing Effectiveness and Risk

This pragmatic trial is designed to test an intervention to increase compliance with guidelines, and generate evidence to assess effectiveness of Primary Prophylactic CSF (PP-CSF) on reducing rates of FN for patients receiving intermediate-risk chemotherapy regimens. TrACER is the first trial of its kind and is sponsored by SWOG, a part of the National Clinical Trials Network. The trial is led by Dr. Scott Ramsey at HICOR and funded in part by PCORI.

STUDY UPDATES

- ✦ As of 11/18/2019, there are **3,568 patients registered** to study.
- ✦ S1415CD was recently featured in **The Front Line**, a blog kept by SWOG Group Chair Charles D. Blanke. You can read the article [here](#).



THANK YOU TO OUR TOP ACCRUERS

CONGRATULATIONS TO WEST MICHIGAN CANCER CENTER FOR REACHING 100% ACCRUAL

CONGRATULATIONS TO OUR TOP ACCRUERS FOR THE MONTH OF OCTOBER:

- ★ Baptist Memorial Health Care in Memphis, TN (7 accruals)
- ★ Essentia Health Cancer Center in Duluth, MN (6 accruals)
- ★ Sanford Medical Center in Fargo, ND (6 accruals)

TrACER Total Accrual as of November 18, 2019



Contact Us

Site Requirements, including regimen questions: HICOR ▪ TrACER@fredhutch.org ▪ 206-667-7624
 Patient eligibility, study procedures, and data submission:
 SWOG SDMC ▪ cancercontrolquestion@crab.org ▪ 206-652-2267